3.31
-0.09(-2.65%)
Currency In USD
Address
Dr. Neergaards Vej
Horsholm, 2970
Denmark
Phone
45 53 53 18 50
Sector
Healthcare
Industry
Biotechnology
Employees
46
First IPO Date
February 05, 2021
| Name | Title | Pay | Year Born |
| Helen Tayton-Martin | Chief Executive Officer | 482,000 | 1967 |
| Thomas Frederik Schmidt | Chief Financial Officer | 77,000 | 1971 |
| Andreas Holm Mattsson | Founder & Chief AI Officer | 326,000 | 1976 |
| Birgitte Rono | Chief Scientific Officer | 343,000 | 1976 |
| Benjamin Ole Wolthers | Vice President of Clinical Development | 0 | N/A |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.